Antimitochondrial antibody-negative primary biliary cirrhosis

Area of Science:

• Immunology
• Hepatology
• Autoimmune Diseases

Background:

• Primary biliary cirrhosis (PBC) is a classic autoimmune liver disease.
• Antimitochondrial antibodies (AMA) are detected in 95% of PBC patients.
• A subset of patients present with PBC despite persistently negative AMA tests.

Purpose of the Study:

• To describe the characteristics of patients with AMA-negative PBC.
• To highlight the clinical equivalence between AMA-positive and AMA-negative PBC.
• To advocate for the adoption of the term AMA-negative PBC.

Main Methods:

• Review of clinical and immunological data from PBC patients.
• Comparison of diagnostic criteria, treatment responses, and prognoses between AMA-positive and AMA-negative groups.
• Analysis of immunologic profiles in AMA-negative PBC patients.

Main Results:

• Patients with AMA-negative PBC exhibit clinically indistinguishable disease from AMA-positive PBC.
• No significant differences in treatment response or prognosis were observed.
• While immunologic profiles may vary, clinical presentation remains consistent.

Conclusions:

• AMA-negative PBC represents a distinct but clinically equivalent entity to classic PBC.
• The term AMA-negative PBC is proposed to replace previous terminology.
• Diagnosis and management strategies for AMA-negative PBC should align with those for AMA-positive PBC.